Select Page

Psoriasis Treatment Market Research Report: Information by Drug Class [Tumour Necrosis Factor Inhibitors (Adalimumab, Infliximab and Etanercept), InterleU.K.in-Inhibitors (Ustekinumab, SecU.K.inumab, Ixekizumab and Brodalumab), Vitamin D Analogues (Calcitriol, Calcipotriol and Tacalcitol)], Treatment Type {Topicals [Over-the-counter (OTC) Topicals, Topical Non-Steroids and Topical Steroids], Systemic (Retinoid, Cyclosporine and Methotrexate), Biologics [Tumour Necrosis Factor Alpha (TNF-α) Inhibitors, InterleU.K.in 12 and 23 (IL-12/23) Inhibitors, InterleU.K.in 17 (IL-17) Inhibitor, T cell Inhibitor]} and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) – Forecast till 2025

Market Synopsis

The Psoriasis Treatment Market Trends 2020 is supposed to witness breakthroughs with the development of new drugs. The market is foreseen to be lucrative in the near future. A report by Market Research Future MRFR underscores that the global psoriasis market is expected to register 7.3% CAGR across the evaluation period 2019 to 2025. It is also projected to touch USD 13.1 Bn mark by the end of 2025.

The patients prone to the disease are generally older adults about 55 years of age. This factor is supposed to influence the growth trajectory of the psoriasis market positively since geriatric population is increasing exponentially. Also, governments are investing in clinical trials and drug discovery. These factors are further supposed to expand the psoriasis market in the near future.

Rising awareness about the treatment has led to acceleration of revenue generation. It has catalyzed investments in preventive care, thus, expanding the psoriasis market. The prevalence rate of the disease ranges from 0.09-11.4% population of most of the countries around the world. It implicates that the disease has a huge patient population and is also supposed to encourage governments to invest in the availability of medical facilities. Hence, the market is supposed to scale new heights in the upcoming years.

Market Segmentation

The psoriasis treatment market, by drug class, is segmented into Tumour Necrosis Factor Inhibitors (Infliximab, Adalimumab, and Etanercept), InterleU.K.in-Inhibitors (Ixekizumab, SecU.K.inumab, Ustekinumab, and Brodalumab), Vitamin D Analogues (Calcipotriol, Calcitriol,and Tacalcitol).

On the basis of treatment type, the psoriasis market has been segmented into topicals (topical non-steroids, over-the-counter OTC topicals, and topical steroids), systemic (cyclosporine, retinoid, and methotrexate), biologics (interleu.k.in 12 and 23 (il-12/23) inhibitors, tumour necrosis factor alpha (TNF-α) inhibitors, t cell inhibitor, and interleu.k.in 17 (il-17) inhibitor).

Browse Complete Report :https://www.marketresearchfuture.com/reports/psoriasis-treatment-market-2769   

Regional Analysis

The geographical study of the global psoriasis market is covered for the following regions – Americas, Europe, Asia-Pacific (APAC), and the Middle East and Africa (MEA). The country based assessment of each of the region is also included in this MRFR report. Americas is supposed to lead the psoriasis market. Increasing patient population, in conjunction with rising geriatric population, is projected to boost the growth curve of the regional market. Also, increasing standardization of drug research and discovery in the region is presumed to augment the psoriasis therapeutics market. It has been seen that the awareness about the disease is increasing. It is anticipated to catalyze preventive medicine sales. This is also supposed to support the expansion of the psoriasis market in the foreseeable future.

Europe is a major region in the psoriasis market. Increasing investments in research & development of drugs are expected to accelerate revenue growth in the region. Asia Pacific is foreseen to exhibit robust growth. The focus of the governments in the development of the healthcare industry is presumed to lead the proliferation of the psoriasis drugs market in the coming years. Also, the population of older adults in the region is rising. It is another major factor prognosticated to develop the psoriasis market in the region. Lastly, the Middle East and Africa region are anticipated to hold the least share of the market. The region is supposed to grow but at a limited pace. Lack of awareness in the underdeveloped regions of the segment poses challenge to market players.

Competitive Dashboard

Novartis International AG (Switzerland), AstraZeneca (UK), UCB (Belgium), Celgene Corporation (US), Pfizer Inc (US), Johnson & Johnson (US), Merck and Co. Inc (US), Amgen (US), AbbVie (US), and Eli Lilly and Company (US) are the major participants of the psoriasis market.

NOTE: Our Team of Researchers are Studying Covid19 and its Impact on Various Industry Verticals and Wherever Required We Will be Considering Covid19 Footprints for a Better Analysis of Markets and Industries. Cordially Get in Touch for More Details.